UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033077
Receipt number R000037704
Scientific Title The supplementary analysis to improve optimal and precision therapy of glomerulonephritis
Date of disclosure of the study information 2018/07/01
Last modified on 2021/05/26 10:15:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The supplementary analysis to improve optimal and precision therapy of glomerulonephritis

Acronym

SUPPORT GN study

Scientific Title

The supplementary analysis to improve optimal and precision therapy of glomerulonephritis

Scientific Title:Acronym

SUPPORT GN study

Region

Japan


Condition

Condition

Renal Diseases
a)IgA nephropathy, purpura nephritis
b)lupus nephritis
c)minimal change nephrotic syndrome, focal segmental glomerulosclerosis
d)ANCA associated vasculitis and related diseases

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate optimal therapy of glomerulonephritis in Japanese patients

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

a. eGFR 30% reduction, end-stage renal disease (initiation of dialysis therapy and renal transplantation) or death
b. complete remission (proteinuria <0.3g/gCr or 0.3g/day)

Key secondary outcomes

a. incomplete remission (proteinuria <1.0g/gCr or 1.0g/day)
b. infectious hospitalization
c. onset of diabetes mellitus
d. cardiovascular event including myocardial infarction, angina pectoris, aortic dissection, aortic rupture and others
e. stroke including cerebral hemorrhage, cerebral infarction, subarachnoid hemorrhage and others
f. cancer


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

the patients who have been enrolled in Nagoya-Kidney Disease Registry (N-KDR) and diagnosed renal diseases indicated below by renal biopsy
a)IgA nephropathy, purpura nephritis
b)lupus nephritis
c)minimal change nephrotic syndrome, focal segmental glomerulosclerosis
d)ANCA associated vasculitis and related diseases

Key exclusion criteria

the patients who refuse consent (consent withdrawal)

Target sample size

6500


Research contact person

Name of lead principal investigator

1st name Shoichi
Middle name
Last name Maruyama

Organization

Nagoya University Graduate School of Medicine, Internal Medicine

Division name

Nephrology

Zip code

464-0056

Address

65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

TEL

+81-52-744-2192

Email

marus@med.nagoya-u.ac.jp


Public contact

Name of contact person

1st name Sawako
Middle name
Last name Kato

Organization

Nagoya University Graduate School of Medicine, Internal Medicine

Division name

Nephrology

Zip code

464-0056

Address

65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

TEL

+81-52-744-2192

Homepage URL


Email

Kato07@med.nagoya-u.ac.jp


Sponsor or person

Institute

Nagoya University Graduate School of Medicine, Nephrology

Institute

Department

Personal name



Funding Source

Organization

CHUGAI PHARMACEUTICAL CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagoya Universiry Graduate School of Medicine

Address

65 Tsurumai-cho, Showa-ku, Nagoya

Tel

052-741-2111

Email

ethics@med.nagoya-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 02 Month 27 Day

Date of IRB

2018 Year 02 Month 27 Day

Anticipated trial start date

2018 Year 02 Month 27 Day

Last follow-up date

2020 Year 05 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Patient characteristics, Pathological findings by renal biopsy, Clinical findings, Treatment history, Treatment outcome.


Management information

Registered date

2018 Year 06 Month 21 Day

Last modified on

2021 Year 05 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037704


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name